Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples